818.93
1.30%
-10.81
前日終値:
$829.74
開ける:
$828
24時間の取引高:
4.65M
Relative Volume:
1.53
時価総額:
$782.99B
収益:
$40.86B
当期純損益:
$8.37B
株価収益率:
151.11
EPS:
5.4193
ネットキャッシュフロー:
$-2.28B
1週間 パフォーマンス:
-8.26%
1か月 パフォーマンス:
-7.41%
6か月 パフォーマンス:
+5.43%
1年 パフォーマンス:
+47.70%
Lilly Eli Co Stock (LLY) Company Profile
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-10-17 | 開始されました | Bernstein | Outperform |
2024-09-13 | 再開されました | Citigroup | Buy |
2024-08-12 | アップグレード | Deutsche Bank | Hold → Buy |
2024-02-21 | ダウングレード | DZ Bank | Buy → Hold |
2024-02-16 | 繰り返されました | Morgan Stanley | Overweight |
2023-12-21 | ダウングレード | Daiwa Securities | Buy → Outperform |
2023-11-09 | 開始されました | Deutsche Bank | Hold |
2023-10-20 | 再開されました | UBS | Buy |
2023-08-09 | アップグレード | Jefferies | Hold → Buy |
2023-07-26 | 繰り返されました | Citigroup | Buy |
2023-07-14 | 開始されました | HSBC Securities | Buy |
2023-05-24 | 繰り返されました | BofA Securities | Buy |
2023-05-24 | 繰り返されました | UBS | Buy |
2023-03-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
2023-03-06 | 開始されました | Jefferies | Hold |
2023-02-15 | ダウングレード | Societe Generale | Hold → Sell |
2022-11-18 | 開始されました | Credit Suisse | Outperform |
2022-09-22 | アップグレード | UBS | Neutral → Buy |
2022-05-23 | 開始されました | SVB Leerink | Outperform |
2022-04-06 | 再開されました | Morgan Stanley | Overweight |
2022-03-10 | 開始されました | Daiwa Securities | Outperform |
2022-01-21 | アップグレード | DZ Bank | Hold → Buy |
2022-01-03 | 繰り返されました | Bernstein | Mkt Perform |
2021-12-17 | 開始されました | Goldman | Neutral |
2021-12-16 | 繰り返されました | BMO Capital Markets | Outperform |
2021-12-16 | 繰り返されました | BofA Securities | Buy |
2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
2021-11-19 | 開始されました | BMO Capital Markets | Outperform |
2021-10-11 | アップグレード | Berenberg | Hold → Buy |
2021-09-29 | アップグレード | Citigroup | Neutral → Buy |
2021-08-05 | アップグレード | DZ Bank | Hold → Buy |
2021-07-27 | 再開されました | Truist | Buy |
2021-06-24 | 繰り返されました | Cantor Fitzgerald | Overweight |
2021-01-19 | アップグレード | Mizuho | Neutral → Buy |
2020-12-10 | アップグレード | Wolfe Research | Peer Perform → Outperform |
2020-11-10 | 再開されました | Bernstein | Mkt Perform |
2020-09-29 | 開始されました | Berenberg | Hold |
2020-09-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2020-06-16 | アップグレード | Guggenheim | Neutral → Buy |
2020-04-21 | ダウングレード | UBS | Buy → Neutral |
2020-04-09 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
2020-02-06 | 開始されました | Mizuho | Neutral |
2019-12-18 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
2019-10-17 | 再開されました | BofA/Merrill | Buy |
2019-05-28 | 開始されました | Goldman | Buy |
2019-04-24 | アップグレード | Edward Jones | Hold → Buy |
2019-04-11 | ダウングレード | Guggenheim | Buy → Neutral |
2019-03-12 | 開始されました | JP Morgan | Overweight |
2019-01-23 | 開始されました | UBS | Buy |
2018-11-26 | ダウングレード | Citigroup | Buy → Neutral |
2018-10-31 | アップグレード | Credit Suisse | Underperform → Neutral |
2018-10-09 | 開始されました | Guggenheim | Buy |
2018-10-01 | 繰り返されました | SunTrust | Buy |
2018-09-26 | 再開されました | JP Morgan | Overweight |
すべてを表示
Lilly Eli Co (LLY) 最新ニュース
Merus annonce ses résultats financiers pour le troisième trimestre 2024 et fait le point sur ses activités - GlobeNewswire Inc.
Eli Lilly grows Milwaukee-area footprint with $40.8M warehouse acquisition — and more - The Business Journals
Hims & Hers Health Faces Pressure Ahead of Earnings Amid Eli Lilly's GLP-1 News - Yahoo Finance UK
Eli Lilly’s Q3 Miss for Mounjaro, Zepbound Highlights Dependency on Wholesalers - BioSpace
Eli Lilly Stock: Is LLY Stock A Sell After Its Disastrous Third-Quarter Report? - Investor's Business Daily
Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip - MSN
ViaNautis signs multi-year collaboration with Eli Lilly and Company - Business Weekly
Friday Five – Humira humbled, Lilly investors get trick instead of treat, Pfizer seeks to show up Starboard… and more - FirstWord Pharma
Eli Lilly and the British government partner to provide GLP-1 weight loss medication to people who have obesity - HR Brew
Lilly’s earnings surprise, investors mull the election, & a spooky ghost story - STAT
Eli Lilly viewed positively despite Mounjaro, Zepbound disappointmentBoA - Proactive Investors USA
Eli Lilly Shares Hit Yearly Low After Disappointing Q3 Earnings - Yahoo Finance
Eli Lilly and Company (NYSE:LLY): Among The 10 Best S&P 500 Stocks to Buy According to Hedge Funds - Insider Monkey
ELI LILLY AND COMPANY : Jefferies remains its Buy rating - Marketscreener.com
Eli Lilly core thesis ‘remains intact’ despite Q3 miss, says JPMorgan - Yahoo Finance
Are Eli Lilly's Lowered Expectations a Reason to Sell? - The Motley Fool
Eli Lilly and Co (LLY) Q3 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ... - Yahoo Finance
Eli Lilly and Co (LLY): A Strategic SWOT Insight into Pharma's Future - Yahoo Finance UK
Nasdaq edges back from its record as chip companies and Eli Lilly slump - The Decatur Daily
Stocks hit pause after Nasdaq milestone; Eli Lilly earnings underwhelm Wall St. - The Post and Courier
Health Care Down as Eli Lilly Slides -- Health Care Roundup - MarketWatch
Eli Lilly & Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Stock market today: Nasdaq edges back from its record as chip companies and Eli Lilly slump - Oneonta Daily Star
Wall Street indexes edge lower Wednesday as Alphabet jumps and Eli Lilly slumps - Greater Milwaukee Today | GMToday.com
AMD, Eli Lilly slide; Google, Visa rise among Wednesday's afternoon market cap stock movers - Investing.com
Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast - Benzinga
Lilly’s Mounjaro, Zepbound drugs see strong demand. So why did sales disappoint? - MarketWatch
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed - CNBC
Eli Lilly’s third quarter earnings miss and forecast cut lead to sharp stock drop - LPHeraldDispatch.com
Knockoff weight loss drugs are having a moment. Eli Lilly isn't worried - Yahoo! Voices
Eli Lilly (LLY) Q3 2024 Earnings Call Transcript - The Motley Fool
Eli Lilly plans to begin advertising weight-loss drug Zepbound - Yahoo Finance
Eli Lilly’s slip does not mean the weight loss drug craze is over - Financial Times
Stock movers: Alphabet, Super Micro, Eli Lilly and more - TheStreet
Stock market today: Wall Street wavers as Alphabet jumps on Google profits and Eli Lilly slumps - Ottumwacourier
Eli Lilly had a strong Q3, so why is its stock falling? - Seeking Alpha
Eli Lilly Earnings: Maintaining Our Fair Value and Long-Term GLP-1 Forecast Despite Weaker Q3 - Morningstar
Lilly Cuts Outlook After Obesity Drug Sales Post First Miss - Bloomberg
Eli Lilly's rare sales miss for weight-loss drug sends shares tumbling - Reuters
Eli Lilly: The Stock Might Have Peaked (NYSE:LLY) - Seeking Alpha
Lilly's Q3 Earnings Miss, Mounjaro, Zepbound Disappoint, Stock Tanks - Yahoo Finance
Lilly cuts outlook on surprising weight-loss drug disappointment - Detroit News
Why Eli Lilly Stock Is Sinking Today - The Motley Fool
Lilly shares tumble on earnings report that falls short of Wall Street expectations - Inside INdiana Business
Stock market today: Wall Street churns near records as Alphabet jumps and Eli Lilly slumps - News-Press Now
Eli Lilly shares tumble as company’s weight-loss drug misses Wall Street sales expectations - The Globe and Mail
Have Eli Lilly's weight-loss drug gains hit a plateau? - Sherwood News
Stock market today: Wall Street churns as Alphabet jumps, Eli Lilly tumbles - Ottumwacourier
Drugmaker Eli Lilly dials back 2024 forecast after 3Q earnings miss - WTHR
Drugmaker Eli Lilly walks back 2024 forecast after 3Q earnings miss - Bozeman Daily Chronicle
Eli Lilly stock sinks after Q3 earnings miss Wall Street expectations - Yahoo Finance
Lilly Eli Co (LLY) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):